JOHNSON & JOHNSON (JNJ) Stock News

USA - NYSE:JNJ - US4781601046 - Common Stock

181.62 USD

+1.91 (+1.06%)

Last: 9/29/2025, 8:04:00 PM

181.65 USD

+0.03 (+0.02%)

Pre-Market: 9/30/2025, 4:08:29 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

JNJ Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill

News Image

Johnson & Johnson (NYSE:JNJ) Shows Strong Technical Setup for Potential Breakout

13 days ago - By: Chartmill

News Image

Johnson & Johnson (NYSE:JNJ): A Dividend Stock with Lasting Financial Strength

19 hours ago - By: Benzinga - Mentions: FTXH MIXJ IHE PBE ...

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

2 days ago - By: The Motley Fool

Why Johnson & Johnson Could Be the Ultimate Dividend King

2 days ago - By: The Motley Fool - Mentions: PLTR AMZN NVDA BAC

Is Palantir Technologies Stock a Buy Now?

4 days ago - By: CNBC

Johnson & Johnson CEO is optimistic about pharma innovation in the U.S. despite industry challenges from the Trump administration

4 days ago - By: Bloomberg

Trump Targets Pharma, Furniture in New Tariff Push

6 days ago - By: Stocktwits - Mentions: KVUE C

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’

7 days ago - By: Benzinga

Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock

7 days ago - By: Stocktwits - Mentions: KVUE

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?

7 days ago - By: Stocktwits - Mentions: KVUE GSK

News Image

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

8 days ago - By: Stocktwits - Mentions: KVUE NWS

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism

11 days ago - By: Johnson & Johnson

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

11 days ago - By: Investor's Business Daily - Mentions: REGN

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?